Published in J Biol Chem on June 02, 2005
Lysine acetylation: codified crosstalk with other posttranslational modifications. Mol Cell (2008) 6.93
The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol (2008) 6.90
HDAC6 modulates cell motility by altering the acetylation level of cortactin. Mol Cell (2007) 3.99
New and emerging HDAC inhibitors for cancer treatment. J Clin Invest (2014) 3.35
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol (2010) 2.94
Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol Cell Biol (2008) 2.85
An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol Cell (2007) 2.75
HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates. Genes Dev (2007) 2.56
The deacetylase HDAC6 is a novel critical component of stress granules involved in the stress response. Genes Dev (2007) 2.43
Histone deacetylase 6 regulates growth factor-induced actin remodeling and endocytosis. Mol Cell Biol (2007) 2.25
The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis. Cancer Res (2008) 2.17
Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression. Genes Dev (2010) 2.14
HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation. Proc Natl Acad Sci U S A (2008) 2.10
Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res (2010) 2.01
Heat shock proteins: essential proteins for apoptosis regulation. J Cell Mol Med (2008) 1.93
Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res (2009) 1.92
Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. Mol Cell Biol (2006) 1.89
Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion. Cancer Res (2008) 1.88
Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cells. Mol Cell Biol (2011) 1.82
The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs (2010) 1.79
Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci U S A (2006) 1.78
A novel histone deacetylase pathway regulates mitosis by modulating Aurora B kinase activity. Genes Dev (2006) 1.70
Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Res (2009) 1.68
Aggresome formation and neurodegenerative diseases: therapeutic implications. Curr Med Chem (2008) 1.68
HDAC inhibitor-based therapies: can we interpret the code? Mol Oncol (2012) 1.67
Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation. J Cell Mol Med (2010) 1.65
Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents. Proc Natl Acad Sci U S A (2010) 1.62
Post-translational modifications of Hsp90 and their contributions to chaperone regulation. Biochim Biophys Acta (2011) 1.56
Proposal for a role of the Hsp90/Hsp70-based chaperone machinery in making triage decisions when proteins undergo oxidative and toxic damage. Exp Biol Med (Maywood) (2010) 1.50
The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood (2010) 1.48
The tale of protein lysine acetylation in the cytoplasm. J Biomed Biotechnol (2010) 1.44
Selective Raf inhibition in cancer therapy. Expert Opin Ther Targets (2007) 1.44
Acetylation goes global: the emergence of acetylation biology. Sci Signal (2009) 1.41
HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers. Breast Cancer Res (2015) 1.40
A chemical probe toolbox for dissecting the cancer epigenome. Nat Rev Cancer (2017) 1.40
Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy. Oncogene (2011) 1.38
Histone deacetylase 6 interacts with the microtubule-associated protein tau. J Neurochem (2008) 1.38
Histone deacetylase 6 regulates human immunodeficiency virus type 1 infection. Mol Biol Cell (2005) 1.37
The microtubule-associated histone deacetylase 6 (HDAC6) regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation. J Biol Chem (2010) 1.36
Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights. Pharmacol Ther (2014) 1.35
Histone deacetylases: target enzymes for cancer therapy. Clin Exp Metastasis (2007) 1.35
Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions. Biochim Biophys Acta (2010) 1.35
The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models. Cancer Res (2011) 1.34
Breast cancer metastasis suppressor 1 (BRMS1) is stabilized by the Hsp90 chaperone. Biochem Biophys Res Commun (2006) 1.33
Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor. Clin Cancer Res (2008) 1.33
Hsp90, an unlikely ally in the war on cancer. FEBS J (2013) 1.33
HDAC6 is required for epidermal growth factor-induced beta-catenin nuclear localization. J Biol Chem (2008) 1.31
Lymphocyte chemotaxis is regulated by histone deacetylase 6, independently of its deacetylase activity. Mol Biol Cell (2006) 1.29
Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. Invest New Drugs (2010) 1.27
New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential. Drug Resist Updat (2009) 1.27
HDAC6 modulates Hsp90 chaperone activity and regulates activation of aryl hydrocarbon receptor signaling. J Biol Chem (2009) 1.26
Acetylated hsp70 and KAP1-mediated Vps34 SUMOylation is required for autophagosome creation in autophagy. Proc Natl Acad Sci U S A (2013) 1.24
New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer. J Hematol Oncol (2009) 1.24
Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression. J Exp Med (2012) 1.23
Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6. Proc Natl Acad Sci U S A (2009) 1.23
Epigenomics and breast cancer. Pharmacogenomics (2008) 1.23
Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells. Clin Cancer Res (2008) 1.23
Apoptotic sensitivity of colon cancer cells to histone deacetylase inhibitors is mediated by an Sp1/Sp3-activated transcriptional program involving immediate-early gene induction. Cancer Res (2010) 1.22
Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate. Blood (2008) 1.18
Heat shock protein 90 inhibition in lung cancer. J Thorac Oncol (2008) 1.18
Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors. Cancer Res (2009) 1.18
Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology (2008) 1.18
Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells. Cancer Biol Ther (2009) 1.16
Histone deacetylase 6 (HDAC6) is an essential modifier of glucocorticoid-induced hepatic gluconeogenesis. Diabetes (2011) 1.15
HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer. Mol Endocrinol (2009) 1.15
Retracted Histone deacetylase inhibitors activate NF-kappaB in human leukemia cells through an ATM/NEMO-related pathway. J Biol Chem (2010) 1.14
Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells. Clin Cancer Res (2010) 1.14
Targeting Huntington's disease through histone deacetylases. Clin Epigenetics (2011) 1.13
Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment. Expert Opin Drug Discov (2011) 1.12
DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines. BMC Med Genomics (2009) 1.12
Berberine suppresses androgen receptor signaling in prostate cancer. Mol Cancer Ther (2011) 1.11
AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated Kit. Blood (2010) 1.11
The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo. PLoS One (2010) 1.11
HDAC6 deacetylates Ku70 and regulates Ku70-Bax binding in neuroblastoma. Neoplasia (2011) 1.11
Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells. PLoS One (2011) 1.09
Uropathogenic Escherichia coli invades host cells via an HDAC6-modulated microtubule-dependent pathway. J Biol Chem (2008) 1.09
Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole. Cancer Res (2011) 1.09
Histone deacetylase inhibitors downregulate checkpoint kinase 1 expression to induce cell death in non-small cell lung cancer cells. PLoS One (2010) 1.09
HDAC6 regulates glucocorticoid receptor signaling in serotonin pathways with critical impact on stress resilience. J Neurosci (2012) 1.08
Targeting HDACs: a promising therapy for Alzheimer's disease. Oxid Med Cell Longev (2011) 1.08
HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo. Clin Cancer Res (2011) 1.06
A novel class of small molecule inhibitors of HDAC6. ACS Chem Biol (2011) 1.05
Exploiting cellular pathways to develop new treatment strategies for AML. Cancer Treat Rev (2010) 1.03
Microtubule acetylation amplifies p38 kinase signalling and anti-inflammatory IL-10 production. Nat Commun (2014) 1.02
Activation of the unfolded protein response contributes toward the antitumor activity of vorinostat. Neoplasia (2010) 1.02
Histone deacetylase inhibitors: the epigenetic therapeutics that repress hypoxia-inducible factors. J Biomed Biotechnol (2010) 1.02
Requirement of histone deacetylase activity for the expression of critical photoreceptor genes. BMC Dev Biol (2007) 1.02
Effects of histone deacetylase inhibitors on HIF-1. Cell Cycle (2006) 1.01
Histone deacetylase 10 promotes autophagy-mediated cell survival. Proc Natl Acad Sci U S A (2013) 1.01
Histone deacetylase inhibitors and cell death. Cell Mol Life Sci (2014) 1.00
Loss of HDAC6, a novel CHIP substrate, alleviates abnormal tau accumulation. Hum Mol Genet (2012) 1.00
Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. Semin Hematol (2009) 1.00
Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group. Bioorg Med Chem (2009) 0.99
Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim. Br J Haematol (2011) 0.99
A microenvironment-mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas. J Clin Invest (2013) 0.99
R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies. Br J Cancer (2007) 0.98
The protein farnesyltransferase regulates HDAC6 activity in a microtubule-dependent manner. J Biol Chem (2009) 0.98
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med (2006) 8.26
Lysine acetylation: codified crosstalk with other posttranslational modifications. Mol Cell (2008) 6.93
The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol (2008) 6.90
Acetylation and deacetylation of non-histone proteins. Gene (2005) 6.87
HDAC6 modulates cell motility by altering the acetylation level of cortactin. Mol Cell (2007) 3.99
PRDI-BF1 recruits the histone H3 methyltransferase G9a in transcriptional silencing. Nat Immunol (2004) 3.39
The interaction between HIV-1 Gag and APOBEC3G. J Biol Chem (2004) 3.27
Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci U S A (2012) 3.03
Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J Biol Chem (2002) 2.82
The draft genome of sweet orange (Citrus sinensis). Nat Genet (2012) 2.81
BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J Leukoc Biol (2012) 2.80
SIRT1 sumoylation regulates its deacetylase activity and cellular response to genotoxic stress. Nat Cell Biol (2007) 2.47
SIRT1 regulates the function of the Nijmegen breakage syndrome protein. Mol Cell (2007) 2.42
Regulation of histone deacetylase activities. J Cell Biochem (2004) 2.41
The interferon-inducible MxB protein inhibits HIV-1 infection. Cell Host Microbe (2013) 2.39
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res (2006) 2.33
Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. Cancer Res (2006) 2.15
Targeted recruitment of a histone H4-specific methyltransferase by the transcription factor YY1. Genes Dev (2003) 2.08
Functional domains of histone deacetylase-3. J Biol Chem (2002) 2.05
Histone deacetylase 3 interacts with and deacetylates myocyte enhancer factor 2. Mol Cell Biol (2006) 2.01
The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu. J Virol (2009) 2.00
The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat Immunol (2008) 1.98
Identification of compounds that enhance the anti-lymphoma activity of rituximab using flow cytometric high-content screening. J Immunol Methods (2004) 1.96
Collaborative spirit of histone deacetylases in regulating chromatin structure and gene expression. Curr Opin Genet Dev (2003) 1.95
Histone deacetylase 3 (HDAC3) activity is regulated by interaction with protein serine/threonine phosphatase 4. Genes Dev (2005) 1.94
Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res (2008) 1.94
Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin. Cancer Res (2005) 1.93
Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion. Cancer Res (2008) 1.88
APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription. J Biol Chem (2007) 1.87
A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci U S A (2009) 1.83
Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin Cancer Res (2006) 1.81
Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1. Blood (2011) 1.73
JNK phosphorylation relieves HDAC3-dependent suppression of the transcriptional activity of c-Jun. EMBO J (2003) 1.67
The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res (2006) 1.67
Regulation of histone deacetylase 2 by protein kinase CK2. J Biol Chem (2002) 1.63
Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2. Clin Cancer Res (2005) 1.62
Chromatin unfolding by Cdt1 regulates MCM loading via opposing functions of HBO1 and HDAC11-geminin. Cell Cycle (2010) 1.62
Negative regulation of histone deacetylase 8 activity by cyclic AMP-dependent protein kinase A. Mol Cell Biol (2004) 1.60
Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells. Mol Cancer Res (2008) 1.59
Coactivators and corepressors of NF-kappaB in IkappaB alpha gene promoter. J Biol Chem (2005) 1.57
Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. Mol Cancer Ther (2006) 1.56
Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation. Cancer Biol Ther (2007) 1.55
NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood (2003) 1.53
Chromosomally integrated human herpesvirus 6: questions and answers. Rev Med Virol (2011) 1.50
Isolation and characterization of a novel class II histone deacetylase, HDAC10. J Biol Chem (2001) 1.48
HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells. Blood (2008) 1.47
Endoplasmic reticulum stress induction of the Grp78/BiP promoter: activating mechanisms mediated by YY1 and its interactive chromatin modifiers. Mol Cell Biol (2005) 1.46
Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells. Mol Cancer Ther (2007) 1.45
Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol Cancer Ther (2003) 1.45
Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90. Clin Cancer Res (2007) 1.42
Reuse of infected cardiac rhythm management devices in the same patients: a single-center experience. Pacing Clin Electrophysiol (2014) 1.40
Post-transcriptional regulatory network of epithelial-to-mesenchymal and mesenchymal-to-epithelial transitions. J Hematol Oncol (2014) 1.39
In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica (2009) 1.38
Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells. Oncogene (2002) 1.38
Association of RNA helicase a with human immunodeficiency virus type 1 particles. J Biol Chem (2006) 1.37
Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. Blood (2006) 1.36
SIRT1 deacetylates the DNA methyltransferase 1 (DNMT1) protein and alters its activities. Mol Cell Biol (2011) 1.35
Inhibition of initiation of reverse transcription in HIV-1 by human APOBEC3F. Virology (2007) 1.35